January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
October 2025 in “Phytochemistry Letters”
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
13 citations
,
January 2017 in “Molecules” Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.
13 citations
,
August 2018 in “Life sciences” Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.
3 citations
,
August 2013 in “Stem cells” Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2024 in “Journal of Investigative Dermatology” ATP-sensitive potassium channels are important for hair growth.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
39 citations
,
March 2009 in “Dermatology Online Journal” Erlotinib can cause persistent excessive hair growth.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
32 citations
,
April 2011 in “Journal of the American Academy of Dermatology” Erlotinib may cause scarring hair loss.
Baricitinib helps regrow hair in teens with severe alopecia areata.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
5 citations
,
December 2018 in “Biological & Pharmaceutical Bulletin” Norgalanthamine helps hair cells grow by activating certain pathways related to hair growth.
6 citations
,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.